Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cetylpyridinium Chloride
Therapeutic Area : Dental and Oral Health
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 18, 2025
Lead Product(s) : Cetylpyridinium Chloride
Therapeutic Area : Dental and Oral Health
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cetylpyridinium Chloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Grammidin neo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 05, 2025
Lead Product(s) : Cetylpyridinium Chloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cetylpyridinium Chloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Grammidin neo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 05, 2025
Lead Product(s) : Cetylpyridinium Chloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cetylpyridinium Chloride
Therapeutic Area : Dental and Oral Health
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 13, 2025
Lead Product(s) : Cetylpyridinium Chloride
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cetylpyridinium Chloride
Therapeutic Area : Dental and Oral Health
Study Phase : Phase III
Sponsor : German Cancer Research Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 23, 2024
Lead Product(s) : Cetylpyridinium Chloride
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase III
Sponsor : German Cancer Research Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cetylpyridinium Chloride
Therapeutic Area : Dental and Oral Health
Study Phase : Phase III
Sponsor : Universidad Autonoma de San Luis Potosí
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 19, 2024
Lead Product(s) : Cetylpyridinium Chloride
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase III
Sponsor : Universidad Autonoma de San Luis Potosí
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cetylpyridinium Chloride
Therapeutic Area : Undisclosed
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Mouthwash in Reducing the Symptoms Associated With Flu and Cold Viruses
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 28, 2024
Lead Product(s) : Cetylpyridinium Chloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cetylpyridinium Chloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Methodex
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Cetylpyridinium Chloride (CPC) Rinse in Viral Upper Respiratory Tract Infections (vURTI)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 09, 2024
Lead Product(s) : Cetylpyridinium Chloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Methodex
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cetylpyridinium Chloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
UH to Launch Clinical Trial in the Fight to Protect Clinicians Against COVID-19
Details : The trial, named the ARMS-I COVID Study, is designed to assess whether ARMS-I helps prevent airborne transmission of coronavirus and whether it reduces the symptoms of healthcare providers who have tested positive for the virus.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 04, 2020
Lead Product(s) : Cetylpyridinium Chloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cetylpyridinium Chloride
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Cross Research S.A.
Deal Size : Inapplicable
Deal Type : Inapplicable
A Novel Mouthwash Formulation CTP/BNZ With Mucus Adhesive Polymer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 16, 2018
Lead Product(s) : Cetylpyridinium Chloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Cross Research S.A.
Deal Size : Inapplicable
Deal Type : Inapplicable